KEELE, United Kingdom, Feb. 5, 2026 — Biocomposites announced that its STIMULAN® Rapid Cure and STIMULAN® Kit have received European Union Medical Device Regulation (MDR) certification for use in combination with multiple antibiotics, including vancomycin, gentamicin, and tobramycin, as well as dual-antibiotic regimens. The certification reinforces the products’ role in localized infection management in bone and surrounding soft tissue, expanding clinical flexibility for surgeons treating complex musculoskeletal infections.
Science Significance
The MDR certification underscores the scientific advancement of STIMULAN® as a calcium sulfate antibiotic carrier matrix engineered for localized drug delivery. Designed to be mixed with both Gram-positive and Gram-negative antibiotics, the system enables targeted antimicrobial release directly at infection sites. This localized delivery allows antibiotic concentrations significantly higher than those achievable through systemic administration, improving bacterial eradication while minimizing systemic toxicity. As the only certified calcium matrix capable of carrying combined antibiotic regimens, STIMULAN® represents a meaningful innovation in orthopedic infection science, particularly in trauma, spine, and prosthetic surgery settings.
Regulatory Significance
Achieving MDR certification marks a critical regulatory milestone under the European Union’s stringent medical device framework. MDR requirements demand comprehensive clinical evaluation, risk assessment, post-market surveillance planning, and quality system validation. Certification confirms that STIMULAN® meets updated EU safety and performance standards for devices used in infection management. The expanded antibiotic compatibility claims also required detailed compatibility testing, sterility assurance validation, and controlled release characterization, reinforcing regulatory confidence in the device’s clinical reliability.
Business Significance
Advertisement
Commercially, MDR certification strengthens Biocomposites’ leadership position in the global infection management device market. STIMULAN® is already approved in more than 60 countries and supports approximately 150,000 patient procedures annually. Regulatory expansion enhances competitive differentiation while enabling broader adoption across European healthcare systems. With global operations spanning Europe, the United States, Asia, and Latin America, Biocomposites is positioned to leverage the certification to drive sales growth, expand distributor networks, and reinforce its reputation in calcium compound biomaterials and bone cement innovation.
Patients’ Significance
For patients, particularly those undergoing orthopedic or reconstructive surgery, localized infection control is critical to recovery outcomes. The use of STIMULAN® enables high-dose antibiotic delivery directly at surgical or infected sites, reducing bacterial persistence and lowering reinfection risk. By helping resolve infection more effectively, the technology can reduce the need for secondary surgical interventions, shorten hospital stays, and improve long-term functional recovery. This is especially impactful in musculoskeletal infections, where systemic antibiotic therapy alone may be insufficient.
Policy Significance
The certification aligns with broader healthcare policy priorities focused on antimicrobial stewardship, surgical infection reduction, and device safety oversight. Technologies that enable localized antibiotic delivery contribute to reduced systemic antibiotic exposure, supporting global strategies to combat antimicrobial resistance. MDR-certified infection management devices also reinforce policy frameworks emphasizing clinical evidence, post-market vigilance, and patient safety transparency across the European medical device landscape.
The MDR certification of STIMULAN® Rapid Cure and STIMULAN® Kit marks a significant advancement in orthopedic infection management technology. By enabling certified combination antibiotic delivery within a calcium matrix platform, the products strengthen surgical infection control strategies while supporting improved patient outcomes. As regulatory standards continue to evolve, innovations such as STIMULAN® highlight the growing importance of compliant, evidence-based medical devices in modern healthcare systems.
Source: Biocomposites press release
